Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 791060, 13 pages
http://dx.doi.org/10.1155/2015/791060
Review Article

Cancer as a Proinflammatory Environment: Metastasis and Cachexia

1Departamento de Fisiologia, Universidade Federal de São Paulo, 04023-062 São Paulo, SP, Brazil
2Universidade de São Paulo, Clínica Cirúrgica, Hospital Universitário, 05508-000 São Paulo, SP, Brazil

Received 25 February 2015; Revised 17 April 2015; Accepted 11 May 2015

Academic Editor: Alessandro Laviano

Copyright © 2015 Nelson Inácio Pinto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Bertolini, S. Orecchioni, J. Petit, and M. G. Kolonin, “Obesity, proinflammatory mediators, adipose tissue progenitors, and breast cancer,” Current Opinion in Oncology, vol. 26, no. 6, pp. 545–550, 2014. View at Publisher · View at Google Scholar
  2. E. E. Calle and R. Kaaks, “Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms,” Nature Reviews Cancer, vol. 4, no. 8, pp. 579–591, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. E. J. Gallagher and D. LeRoith, “Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer,” Diabetes Care, vol. 36, supplement 2, pp. S233–S239, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. S. D. Hursting and M. J. Hursting, “Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 8, pp. 1766–1770, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S. S. Ganguly, X. Li, and C. K. Miranti, “The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis,” Frontiers in Oncology, vol. 4, article 364, 2014. View at Publisher · View at Google Scholar
  6. J. T. Serviss, P. Johnsson, and D. Grander, “An emerging role for long non-coding RNAs in cancer metastasis,” Frontiers in Genetics, vol. 5, article 234, 2014. View at Publisher · View at Google Scholar
  7. R. C. Bates and A. M. Mercurio, “Tumor necrosis factor-α stimulates the epithelial-to-mesenchymal transition of human colonic organoids,” Molecular Biology of the Cell, vol. 14, no. 5, pp. 1790–1800, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. D. E. Sullivan, M. Ferris, H. Nguyen, E. Abboud, and A. R. Brody, “TNF-α induces TGF-β1 expression in lung fibroblasts at the transcriptional level via AP-1 activation,” Journal of Cellular and Molecular Medicine, vol. 13, no. 8, pp. 1866–1876, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Trayhurn and I. S. Wood, “Adipokines: inflammation and the pleiotropic role of white adipose tissue,” The British Journal of Nutrition, vol. 92, no. 3, pp. 347–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. C. Seelaender and M. L. Batista, “Adipose tissue inflammation and cancer cachexia: the role of steroid hormones,” Hormone Molecular Biology and Clinical Investigation, vol. 17, no. 1, pp. 5–12, 2014. View at Publisher · View at Google Scholar
  11. L. K. Chopin, I. Seim, C. M. Walpole, and A. C. Herington, “The Ghrelin axis-does it have an appetite for cancer progression?” Endocrine Reviews, vol. 33, no. 6, pp. 849–891, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. P. E. Porporato, N. Filigheddu, S. Reano et al., “Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice,” The Journal of Clinical Investigation, vol. 123, no. 2, pp. 611–622, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Bonetto, F. Penna, V. G. Minero et al., “Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice,” Current Cancer Drug Targets, vol. 9, no. 5, pp. 608–616, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Costelli, M. Muscaritoli, A. Bonetto et al., “Muscle myostatin signalling is enhanced in experimental cancer cachexia,” European Journal of Clinical Investigation, vol. 38, no. 7, pp. 531–538, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Tsuchida, “Targeting myostatin for therapies against muscle-wasting disorders,” Current Opinion in Drug Discovery and Development, vol. 11, no. 4, pp. 487–494, 2008. View at Google Scholar · View at Scopus
  16. A. C. McPherron, A. M. Lawler, and S.-J. Lee, “Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member,” Nature, vol. 387, no. 6628, pp. 83–90, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Tsuchida, M. Nakatani, A. Uezumi, T. Murakami, and X. Cui, “Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer,” Endocrine Journal, vol. 55, no. 1, pp. 11–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Garofalo and E. Surmacz, “Leptin and cancer,” Journal of Cellular Physiology, vol. 207, no. 1, pp. 12–22, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Bouloumié, H. C. A. Drexler, M. Lafontan, and R. Busse, “Leptin, the product of Ob gene, promotes angiogenesis,” Circulation Research, vol. 83, no. 10, pp. 1059–1066, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. M. R. Sierra-Honigmann, A. K. Nath, C. Murakami et al., “Biological action of leptin as an angiogenic factor,” Science, vol. 281, no. 5383, pp. 1683–1686, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. E. B. Rankin and A. J. Giaccia, “The role of hypoxia-inducible factors in tumorigenesis,” Cell Death and Differentiation, vol. 15, no. 4, pp. 678–685, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Mazumdar, M. M. Hickey, D. K. Pant et al., “HIF-2α deletion promotes Kras-driven lung tumor development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 32, pp. 14182–14187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. González-Muniesa, C. de Oliveira, F. Pérez de Heredia, M. P. Thompson, and P. Trayhurn, “Fatty acids and hypoxia stimulate the expression and secretion of the adipokine ANGPTL4 (angiopoietin-like protein 4/ fasting-induced adipose factor) by human adipocytes,” Journal of Nutrigenetics and Nutrigenomics, vol. 4, no. 3, pp. 146–153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Trayhurn, “Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity,” Annual Review of Nutrition, vol. 34, no. 1, pp. 207–236, 2014. View at Publisher · View at Google Scholar
  25. D. Liao, C. Corle, T. N. Seagroves, and R. S. Johnson, “Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression,” Cancer Research, vol. 67, no. 2, pp. 563–572, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. J. Liu, G. L. Semenza, and H. F. Zhang, “Hypoxia-inducible factor 1 and breast cancer metastasis,” Journal of Zhejiang University Science B, vol. 16, no. 1, pp. 32–43, 2015. View at Publisher · View at Google Scholar
  27. V. L. Payen, L. Brisson, M. W. Dewhirst, and P. Sonveaux, “Common responses of tumors and wounds to hypoxia,” Cancer Journal, vol. 21, no. 2, pp. 75–87, 2015. View at Publisher · View at Google Scholar
  28. H. Z. Imtiyaz and M. C. Simon, “Hypoxia-inducible factors as essential regulators of inflammation,” Current Topics in Microbiology and Immunology, vol. 345, no. 1, pp. 105–120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Kumar and D. I. Gabrilovich, “Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment,” Immunology, vol. 143, no. 4, pp. 512–519, 2014. View at Publisher · View at Google Scholar
  30. J.-Y. Blay, S. Negrier, V. Combaret et al., “Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma,” Cancer Research, vol. 52, no. 12, pp. 3317–3322, 1992. View at Google Scholar · View at Scopus
  31. N. Hoosein, M. Abdul, R. McCabe et al., “Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer,” Urologic Oncology: Seminars and Original Investigations, vol. 1, no. 6, pp. 246–251, 1995. View at Publisher · View at Google Scholar · View at Scopus
  32. Q. Chang, E. Bournazou, P. Sansone et al., “The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis,” Neoplasia, vol. 15, no. 7, pp. 848–862, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Bonetto, T. Aydogdu, X. Jin et al., “JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia,” The American Journal of Physiology: Endocrinology and Metabolism, vol. 303, no. 3, pp. E410–E421, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Haddad, F. Zaldivar, D. M. Cooper, and G. R. Adams, “IL-6-induced skeletal muscle atrophy,” Journal of Applied Physiology, vol. 98, no. 3, pp. 911–917, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Schéle, A. Benrick, L. Grahnemo et al., “Inter-relation between interleukin (IL)-1, IL-6 and body fat regulating circuits of the hypothalamic arcuate nucleus,” Journal of Neuroendocrinology, vol. 25, no. 6, pp. 580–589, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Amitani, A. Asakawa, H. Amitani, and A. Inui, “Control of food intake and muscle wasting in cachexia,” The International Journal of Biochemistry and Cell Biology, vol. 45, no. 10, pp. 2179–2185, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Wallenius, V. Wallenius, D. Sunter, S. L. Dickson, and J.-O. Jansson, “Intracerebroventricular interleukin-6 treatment decreases body fat in rats,” Biochemical and Biophysical Research Communications, vol. 293, no. 1, pp. 560–565, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. J. M. Argilés, F. J. López-Soriano, and S. Busquets, “Counteracting inflammation: a promising therapy in cachexia,” Critical Reviews in Oncogenesis, vol. 17, no. 3, pp. 253–262, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Fanzani, V. M. Conraads, F. Penna, and W. Martinet, “Molecular and cellular mechanisms of skeletal muscle atrophy: an update,” Journal of Cachexia, Sarcopenia and Muscle, vol. 3, no. 3, pp. 163–179, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Landskron, M. de la Fuente, P. Thuwajit, C. Thuwajit, and M. A. Hermoso, “Chronic inflammation and cytokines in the tumor microenvironment,” Journal of Immunology Research, vol. 2014, Article ID 149185, 19 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Philips and C. Leeuwenburgh, “Muscle fiber specific apoptosis and TNF-α signaling in sarcopenia are attenuated by life-long calorie restriction,” The FASEB Journal, vol. 19, no. 6, pp. 668–670, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. M. E. Amaral, R. Barbuio, M. Milanski et al., “Tumor necrosis factor-α activates signal transduction in hypothalamus and modulates the expression of pro-inflammatory proteins and orexigenic/anorexigenic neurotransmitters,” Journal of Neurochemistry, vol. 98, no. 1, pp. 203–212, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Zhu, Y. Y. Goh, H. F. A. Chin, S. Kersten, and N. S. Tan, “Angiopoietin-like 4: a decade of research,” Bioscience Reports, vol. 32, no. 3, pp. 211–219, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. X.-F. Huang, J. Han, X.-T. Hu, and C. He, “Mechanisms involved in biological behavior changes associated with Angptl4 expression in colon cancer cell lines,” Oncology Reports, vol. 27, no. 5, pp. 1541–1547, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Shibata, T. Nakayama, H. Hirakawa, S. Hidaka, and T. Nagayasu, “Clinicopathological significance of angiopoietin-like protein 4 expression in oesophageal squamous cell carcinoma,” Journal of Clinical Pathology, vol. 63, no. 12, pp. 1054–1058, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Zhu, M. J. Tan, R.-L. Huang et al., “Angiopoietin-like 4 protein elevates the prosurvival intracellular O2-:H2O2 ratio and confers anoikis resistance to tumors,” Cancer Cell, vol. 19, no. 3, pp. 401–415, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. E. T. Ifon, A. L. Y. Pang, W. Johnson et al., “U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3,” Cancer Cell International, vol. 5, article 19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Mandard, F. Zandbergen, E. van Straten et al., “The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity,” The Journal of Biological Chemistry, vol. 281, no. 2, pp. 934–944, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. H.-K. Kim, B.-S. Youn, M.-S. Shin et al., “Hypothalamic Angptl4/Fiaf is a novel regulator of food intake and body weight,” Diabetes, vol. 59, no. 11, pp. 2772–2780, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. W. J. Evans, J. E. Morley, J. Argilés et al., “Cachexia: a new definition,” Clinical Nutrition, vol. 27, no. 6, pp. 793–799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. T. R. Balstad, T. S. Solheim, F. Strasser, S. Kaasa, and A. Bye, “Dietary treatment of weight loss in patients with advanced cancer and cachexia: a systematic literature review,” Critical Reviews in Oncology/Hematology, vol. 91, no. 2, pp. 210–221, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. K. C. H. Fearon, “The 2011 ESPEN Arvid Wretlind lecture: cancer cachexia: the potential impact of translational research on patient-focused outcomes,” Clinical Nutrition, vol. 31, no. 5, pp. 577–582, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. S. von Haehling and S. D. Anker, “Cachexia as a major underestimated and unmet medical need: facts and numbers,” Journal of Cachexia, Sarcopenia and Muscle, vol. 1, no. 1, pp. 1–5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. J. A. Palesty and S. J. Dudrick, “What we have learned about cachexia in gastrointestinal cancer,” Digestive Diseases, vol. 21, no. 3, pp. 198–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. A. J. Bazzan, A. B. Newberg, W. C. Cho, and D. A. Monti, “Diet and nutrition in cancer survivorship and palliative care,” Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID 917647, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Rui, “Brain regulation of energy balance and body weight,” Reviews in Endocrine and Metabolic Disorders, vol. 14, no. 4, pp. 387–407, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Kojima and K. Kangawa, “Ghrelin discovery: a decade after,” Endocrine Development, vol. 25, pp. 1–4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. J. M. Garcia, M. Garcia-Touza, R. A. Hijazi et al., “Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia,” The Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 5, pp. 2920–2926, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. N. Fujitsuka, A. Asakawa, Y. Uezono et al., “Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival,” Translational Psychiatry, vol. 1, article e23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Northrup, K. Kuroda, E. M. Duus et al., “Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model,” Supportive Care in Cancer, vol. 21, no. 9, pp. 2409–2415, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Lenk, S. Palus, R. Schur et al., “Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model,” Journal of Cachexia, Sarcopenia and Muscle, vol. 4, no. 1, pp. 63–69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. Z. Aversa, A. Bonetto, F. Penna et al., “Changes in myostatin signaling in non-weight-losing cancer patients,” Annals of Surgical Oncology, vol. 19, no. 4, pp. 1350–1356, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Elkina, S. von Haehling, S. D. Anker, and J. Springer, “The role of myostatin in muscle wasting: an overview,” Journal of Cachexia, Sarcopenia and Muscle, vol. 2, no. 3, pp. 143–151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. S.-J. Lee and A. C. McPherron, “Regulation of myostatin activity and muscle growth,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 16, pp. 9306–9311, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Reisz-Porszasz, S. Bhasin, J. N. Artaza et al., “Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin,” American Journal of Physiology: Endocrinology and Metabolism, vol. 285, no. 4, pp. E876–E888, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Lokireddy, I. W. Wijesoma, S. Bonala et al., “Myostatin is a novel tumoral factor that induces cancer cachexia,” The Biochemical Journal, vol. 446, no. 1, pp. 23–36, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. M. E. B. Klimek, T. Aydogdu, M. J. Link, M. Pons, L. G. Koniaris, and T. A. Zimmers, “Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia,” Biochemical and Biophysical Research Communications, vol. 391, no. 3, pp. 1548–1554, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. X. Zhou, J. L. Wang, J. Lu et al., “Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival,” Cell, vol. 142, no. 4, pp. 531–543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Margetic, C. Gazzola, G. G. Pegg, and R. A. Hill, “Leptin: a review of its peripheral actions and interactions,” International Journal of Obesity, vol. 26, no. 11, pp. 1407–1433, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Munzberg and C. D. Morrison, “production and signaling of leptin,” Metabolism: Clinical and Experimental, vol. 64, no. 1, pp. 13–23, 2015. View at Google Scholar
  71. G. Ambrosini, A. K. Nath, M. Rocío Sierra-Honigmann, and J. Flores-Riveros, “Transcriptional activation of the human leptin gene in response to hypoxia. Involvement of hypoxia-inducible factor 1,” The Journal of Biological Chemistry, vol. 277, no. 37, pp. 34601–34609, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Ando, I. Barone, C. Giordano, D. Bonofiglio, and S. Catalano, “The multifaceted mechanism of Leptin signaling within tumor microenvironment in driving breast cancer growth and progression,” Frontiers in Oncology, vol. 4, article 340, 2014. View at Publisher · View at Google Scholar
  73. M. Artwohl, M. Roden, T. Hölzenbein, A. Freudenthaler, W. Waldhäusl, and S. M. Baumgartner-Parzer, “Modulation by leptin of proliferation and apoptosis in vascular endothelial cells,” International Journal of Obesity and Related Metabolic Disorders, vol. 26, no. 4, pp. 577–580, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Oda, T. Taniguchi, and M. Yokoyama, “Leptin stimulates rat aortic smooth muscle cell proliferation and migration,” The Kobe Journal of Medical Sciences, vol. 47, no. 3, pp. 141–150, 2001. View at Google Scholar · View at Scopus
  75. J. C. H. Hardwick, G. R. van den Brink, G. J. Offerhaus, S. J. H. van Deventer, and M. P. Peppelenbosch, “Leptin is a growth factor for colonic epithelial cells,” Gastroenterology, vol. 121, no. 1, pp. 79–90, 2001. View at Publisher · View at Google Scholar · View at Scopus
  76. Z. Liu, T. Uesaka, H. Watanabe, and N. Kato, “High fat diet enhances colonic cell proliferation and carcinogenesis in rats by elevating serum leptin,” International Journal of Oncology, vol. 19, no. 5, pp. 1009–1014, 2001. View at Google Scholar · View at Scopus
  77. M.-N. Dieudonne, F. Machinal-Quelin, V. Serazin-Leroy, M.-C. Leneveu, R. Pecquery, and Y. Giudicelli, “Leptin mediates a proliferative response in human MCF7 breast cancer cells,” Biochemical and Biophysical Research Communications, vol. 293, no. 1, pp. 622–628, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. K. Laud, I. Gourdou, L. Pessemesse, J. P. Peyrat, and J. Djiane, “Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line,” Molecular and Cellular Endocrinology, vol. 188, no. 1-2, pp. 219–226, 2002. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Ishikawa, J. Kitayama, and H. Nagawa, “Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer,” Clinical Cancer Research, vol. 10, no. 13, pp. 4325–4331, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. I. Wolf, S. Sadetzki, H. Kanely et al., “Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients,” Cancer, vol. 106, no. 4, pp. 966–973, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. C. Bing, S. Taylor, M. J. Tisdale, and G. Williams, “Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y,” Journal of Neurochemistry, vol. 79, no. 5, pp. 1004–1012, 2001. View at Publisher · View at Google Scholar · View at Scopus
  82. D. Dutta, S. Ghosh, K. Pandit, P. Mukhopadhyay, and S. Chowdhury, “Leptin and cancer: pathogenesis and modulation,” Indian Journal of Endocrinology and Metabolism, vol. 16, supplement 3, pp. S596–S600, 2012. View at Publisher · View at Google Scholar
  83. B. Keith, R. S. Johnson, and M. C. Simon, “HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression,” Nature Reviews Cancer, vol. 12, no. 1, pp. 9–22, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. W. K. Ranasinghe, G. S. Baldwin, D. Bolton, A. Shulkes, J. Ischia, and O. Patel, “HIF1α expression under normoxia in prostate cancer—which pathways to target?” The Journal of Urology, vol. 193, no. 3, pp. 763–770, 2015. View at Publisher · View at Google Scholar
  85. A. J. Giaccia, “HIF-2: the missing link between obesity and cardiomyopathy,” Journal of the American Heart Association, vol. 2, no. 6, Article ID e000710, 2013. View at Publisher · View at Google Scholar
  86. C. Befani, I. Mylonis, I.-M. Gkotinakou et al., “Cobalt stimulates HIF-1-dependent but inhibits HIF-2-dependent gene expression in liver cancer cells,” The International Journal of Biochemistry and Cell Biology, vol. 45, no. 11, pp. 2359–2368, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Cascio, V. Bartella, A. Auriemma et al., “Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1α,” Oncogene, vol. 27, no. 4, pp. 540–547, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Ren, L. Jia, T. Zhao et al., “Hypoxia inducible factor (HIF)-1α directly activates leptin receptor (Ob-R) in pancreatic cancer cells,” Cancer Letters, vol. 354, no. 1, pp. 172–180, 2014. View at Publisher · View at Google Scholar
  89. P. Madanecki, N. Kapoor, Z. Bebok, R. Ochocka, J. F. Collawn, and R. Bartoszewski, “Regulation of angiogenesis by hypoxia: the role of microRNA,” Cellular and Molecular Biology Letters, vol. 18, no. 1, pp. 47–57, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. C. J. Schofield and P. J. Ratcliffe, “Oxygen sensing by HIF hydroxylases,” Nature Reviews Molecular Cell Biology, vol. 5, no. 5, pp. 343–354, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Koshiji, Y. Kageyama, E. A. Pete, I. Horikawa, J. C. Barrett, and L. E. Huang, “HIF-1α induces cell cycle arrest by functionally counteracting Myc,” The EMBO Journal, vol. 23, no. 9, pp. 1949–1956, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. R. A. Guyer and I. G. Macara, “Loss of the polarity protein PAR3 activates STAT3 signaling via an atypical protein kinase C (aPKC)/NF-κB/interleukin-6 (IL-6) axis in mouse mammary cells,” The Journal of Biological Chemistry, vol. 290, no. 13, pp. 8457–8468, 2015. View at Publisher · View at Google Scholar
  93. K. L. Hetzler, J. P. Hardee, M. J. Puppa et al., “Sex differences in the relationship of IL-6 signaling to cancer cachexia progression,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1852, no. 5, pp. 816–825, 2014. View at Publisher · View at Google Scholar
  94. M. L. Batista, M. Olivan, P. S. M. Alcantara et al., “Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients,” Cytokine, vol. 61, no. 2, pp. 532–539, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. S.-Y. Suh, Y. S. Choi, C. H. Yeom et al., “Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer,” Supportive Care in Cancer, vol. 21, no. 11, pp. 3071–3077, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. H. J. Kim, J. Yun, K. H. Kim et al., “Pathophysiological role of hormones and cytokines in cancer cachexia,” Journal of Korean Medical Science, vol. 27, no. 2, pp. 128–134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. M. J. Puppa, J. P. White, S. Sato, M. Cairns, J. W. Baynes, and J. A. Carson, “Gut barrier dysfunction in the ApcMin/+ mouse model of colon cancer cachexia,” Biochimica et Biophysica Acta, vol. 1812, no. 12, pp. 1601–1606, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. F. F. Donatto, R. X. Neves, F. O. Rosa et al., “Resistance exercise modulates lipid plasma profile and cytokine content in the adipose tissue of tumour-bearing rats,” Cytokine, vol. 61, no. 2, pp. 426–432, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. F. S. Lira, A. S. Yamashita, J. C. Rosa et al., “Exercise training decreases adipose tissue inflammation in cachectic rats,” Hormone and Metabolic Research, vol. 44, no. 2, pp. 91–98, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. H. Bielefeldt-Ohmann, A. L. Marzo, R. P. Himbeck, A. G. Jarnicki, B. W. S. Robinson, and D. R. Fitzpatrick, “Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon α immunotherapy,” Cancer Immunology Immunotherapy, vol. 40, no. 4, pp. 241–250, 1995. View at Publisher · View at Google Scholar · View at Scopus
  101. Y. Takahashi, K. Yasumoto, and M. Mai, “Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy,” Oncology Reports, vol. 14, no. 1, pp. 135–140, 2005. View at Google Scholar · View at Scopus
  102. S. K. Patra and S. Arora, “Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome,” Clinica Chimica Acta, vol. 413, no. 13-14, pp. 1025–1034, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. P. Trayhurn and C. Bing, “Appetite and energy balance signals from adipocytes,” Philosophical Transactions of the Royal Society of London B: Biological Sciences, vol. 361, no. 1471, pp. 1237–1249, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. V. Rotter, I. Nagaev, and U. Smith, “Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects,” The Journal of Biological Chemistry, vol. 278, no. 46, pp. 45777–45784, 2003. View at Publisher · View at Google Scholar · View at Scopus
  105. K. Shizuya, T. Komori, R. Fujiwara, S. Miyahara, M. Ohmori, and J. Nomura, “The expressions of mRNAs for interleukin-6 (IL-6) and the IL-6 receptor (IL-6R) in the rat hypothalamus and midbrain during restraint stress,” Life Sciences, vol. 62, no. 25, pp. 2315–2320, 1998. View at Publisher · View at Google Scholar · View at Scopus
  106. Y. Wu, J. Deng, P. G. Rychahou, S. Qiu, B. M. Evers, and B. P. Zhou, “Stabilization of snail by NF-κB is required for inflammation-induced cell migration and invasion,” Cancer Cell, vol. 15, no. 5, pp. 416–428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. F. Balkwill, “TNF-α in promotion and progression of cancer,” Cancer and Metastasis Reviews, vol. 25, no. 3, pp. 409–416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. S. D. Hursting, J. DiGiovanni, A. J. Dannenberg et al., “Obesity, energy balance, and cancer: new opportunities for prevention,” Cancer Prevention Research, vol. 5, no. 11, pp. 1260–1272, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. S. Kim, T. O. Keku, C. Martin et al., “Circulating levels of inflammatory cytokines and risk of colorectal adenomas,” Cancer Research, vol. 68, no. 1, pp. 323–328, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. E. A. Havell, W. Fiers, and R. J. North, “The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity,” The Journal of Experimental Medicine, vol. 167, no. 3, pp. 1067–1085, 1988. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Maachi, L. Piéroni, E. Bruckert et al., “Systemic low-grade inflammation is related to both circulating and adipose tissue TNFα, leptin and IL-6 levels in obese women,” International Journal of Obesity, vol. 28, no. 8, pp. 993–997, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. L. G. Melstrom, K. A. Melstrom Jr., X.-Z. Ding, and T. E. Adrian, “Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia,” Histology and Histopathology, vol. 22, no. 7–9, pp. 805–814, 2007. View at Google Scholar · View at Scopus
  113. L. Zhang, H. Tang, Y. Kou et al., “MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia,” Journal of Cancer Research and Clinical Oncology, vol. 139, no. 7, pp. 1105–1115, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. C.-M. Liu, Z. Yang, C.-W. Liu et al., “Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice,” Gene Therapy, vol. 15, no. 3, pp. 155–160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. B. Pajak, S. Orzechowska, B. Pijet et al., “Crossroads of cytokine signaling—the chase to stop muscle cachexia,” Journal of Physiology and Pharmacology, vol. 59, supplement 9, pp. 251–264, 2008. View at Google Scholar · View at Scopus
  116. A. J. Karayiannakis, K. N. Syrigos, A. Polychronidis, M. Pitiakoudis, A. Bounovas, and K. Simopoulos, “Serum levels of tumor necrosis factor-α and nutritional status in pancreatic cancer patients,” Anticancer Research, vol. 21, no. 2 B, pp. 1355–1358, 2001. View at Google Scholar · View at Scopus
  117. O. Kemik, A. S. Kemik, H. Begenik et al., “The relationship among acute-phase responce proteins, cytokines, and hormones in various gastrointestinal cancer types patients with cachectic,” Human & Experimental Toxicology, vol. 31, no. 2, pp. 117–125, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. S. T. Gulen, F. Karadag, A. B. Karul et al., “Adipokines and systemic inflammation in weight-losing lung cancer patients,” Lung, vol. 190, no. 3, pp. 327–332, 2012. View at Publisher · View at Google Scholar · View at Scopus
  119. A. Aguilera, R. Codoceo, R. Selgas et al., “Anorexigen (TNF-α, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters,” Nephrology Dialysis Transplantation, vol. 13, no. 6, pp. 1476–1483, 1998. View at Publisher · View at Google Scholar · View at Scopus
  120. A. P. Arruda, M. Milanski, T. Romanatto et al., “Hypothalamic actions of tumor necrosis factor α provide the thermogenic core for the wastage syndrome in cachexia,” Endocrinology, vol. 151, no. 2, pp. 683–694, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. S. Busquets, D. Sanchís, B. Alvarez, D. Ricquier, F. J. López-Soriano, and J. M. Argilés, “In the rat, tumor necrosis factor α administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis?” FEBS Letters, vol. 440, no. 3, pp. 348–350, 1998. View at Publisher · View at Google Scholar · View at Scopus
  122. C. H. C. Dejong, S. Busquets, A. G. W. Moses et al., “Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia,” Oncology Reports, vol. 14, no. 1, pp. 257–263, 2005. View at Google Scholar · View at Scopus
  123. Y. Wang, H. Wang, V. Hegde et al., “Interplay of pro-and anti-inflammatory cytokines to determine lipid accretion in adipocytes,” International Journal of Obesity, vol. 37, no. 11, pp. 1490–1498, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. P. Plomgaard, C. P. Fischer, T. Ibfelt, B. K. Pedersen, and G. Van Hall, “Tumor necrosis factor-α modulates human in vivo lipolysis,” The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 2, pp. 543–549, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. S. Kersten, “Regulation of lipid metabolism via angiopoietin-like proteins,” Biochemical Society Transactions, vol. 33, no. 5, pp. 1059–1062, 2005. View at Publisher · View at Google Scholar · View at Scopus
  126. J. Cliff Yoon, T. W. Chickering, E. D. Rosen et al., “Peroxisome proliferator-activated receptor γ target gene encoding a novel angiopoietin-related protein associated with adipose differentiation,” Molecular and Cellular Biology, vol. 20, no. 14, pp. 5343–5349, 2000. View at Publisher · View at Google Scholar · View at Scopus
  127. S. Romeo, L. A. Pennacchio, Y. Fu et al., “Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL,” Nature Genetics, vol. 39, no. 4, pp. 513–516, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Dutton and P. Trayhurn, “Regulation of angiopoietin-like protein 4/fasting-induced adipose factor (Angptl4/FIAF) expression in mouse white adipose tissue and 3T3-L1 adipocytes,” British Journal of Nutrition, vol. 100, no. 1, pp. 18–26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. T. Hato, M. Tabata, and Y. Oike, “The role of angiopoietin-like proteins in angiogenesis and metabolism,” Trends in Cardiovascular Medicine, vol. 18, no. 1, pp. 6–14, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. M. J. Tan, Z. Teo, M. K. Sng, P. Zhu, and N. S. Tan, “Emerging roles of angiopoietin-like 4 in human cancer,” Molecular Cancer Research, vol. 10, no. 6, pp. 677–688, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. Y.-H. Yang, Y. Wang, K. S. L. Lam et al., “Suppression of the Raf/MEK/ERK Signaling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietin-like protein 4,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 5, pp. 835–840, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. X. Lei, F. Shi, D. Basu et al., “Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity,” The Journal of Biological Chemistry, vol. 286, no. 18, pp. 15747–15756, 2011. View at Publisher · View at Google Scholar · View at Scopus
  133. H. M. C. Shantha Kumara, D. Kirchoff, S. A. Herath et al., “Plasma levels of angiopoietin-like protein 4 (ANGPTL4) are significantly lower preoperatively in colorectal cancer patients than in cancer-free patients and are further decreased during the first month after minimally invasive colorectal resection,” Surgical Endoscopy, vol. 26, no. 10, pp. 2751–2757, 2012. View at Publisher · View at Google Scholar · View at Scopus
  134. A. Galaup, A. Cazes, S. Le Jan et al., “Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 49, pp. 18721–18726, 2006. View at Publisher · View at Google Scholar · View at Scopus
  135. S. Le Jan, C. Amy, A. Cazes et al., “Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma,” The American Journal of Pathology, vol. 162, no. 5, pp. 1521–1528, 2003. View at Publisher · View at Google Scholar · View at Scopus
  136. N. Toshiyuki, H. Hiroshi, S. Kenichiro et al., “Expression of angiopoietin-like 4 (ANGPTL4) in human colorectal cancer: ANGPTL4 promotes venous invasion and distant metastasis,” Oncology Reports, vol. 25, no. 4, pp. 929–935, 2011. View at Publisher · View at Google Scholar · View at Scopus
  137. E. E. Girroir, H. E. Hollingshead, A. N. Billin et al., “Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines,” Toxicology, vol. 243, no. 1-2, pp. 236–243, 2008. View at Publisher · View at Google Scholar · View at Scopus
  138. H. Li, C. Ge, F. Zhao et al., “Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin beta1 signaling in human hepatocellular carcinoma,” Hepatology, vol. 54, no. 3, pp. 910–919, 2011. View at Google Scholar
  139. S.-H. Kim, Y.-Y. Park, S.-W. Kim, J.-S. Lee, D. Wang, and R. N. DuBois, “ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression,” Cancer Research, vol. 71, no. 22, pp. 7010–7020, 2011. View at Publisher · View at Google Scholar · View at Scopus
  140. L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome-proliferator-activated receptors and cancers: complex stories,” Nature Reviews Cancer, vol. 4, no. 1, pp. 61–70, 2004. View at Publisher · View at Google Scholar · View at Scopus